Abstract
Ureido tertiary amide derivatives are claimed as antagonists of the 4β1integrin receptor (VLA-4). They inhibit the binding of adhesion molecules such as VCAM-1 (vascular cell adhesion molecule-1) and fibronectin to this integrin receptor. Such compounds are useful in the treatment of a range of inflammatory diseases such as asthma.